Jci_page_head_homepage_01 Jci_page_head_homepage_02
Noriaki Okamoto, Risa Chihara, Chiori Shimizu, Sogo Nishimoto, Takeshi Watanabe
Published in Volume 117, Issue 4
J Clin Invest. 2007; 117(4):997–1007 doi:10.1172/JCI30379
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 2
Generation of aLNs.

Immunohistochemical staining shows that aLNs formed in NP-OVA–preimmunized EGFP transgenic BALB/c mice (AF). After their formation, aLNs were removed and transplanted into renal subcapsular regions of SCID mice, and then mice were immunized intravenously with NP-OVA. Immunohistochemical staining in the spleens of SCID mouse recipients carrying aLNs (G and H). Spleen cells were examined after the second immunization with NP-OVA. Increased numbers of IgG1 AFCs (G), compared with few IgG2 AFCs (H), were observed in SCID mouse spleens. Antibodies used were as follows: biotin-labeled anti-mouse B220 and Qdot 605 streptavidin conjugate (A); anti-mouse FDC-M1 and Alexa Fluor 594 conjugate (B); biotin-labeled anti-mouse CD11c and Qdot 605 streptavidin conjugate (C); biotin-labeled anti-mouse CD3 and Qdot 605 streptavidin conjugate; biotin-labeled anti-mouse CD4 and Qdot 605 streptavidin conjugate (E); biotin-labeled anti-mouse CD8 and Qdot 605 streptavidin conjugate (F); biotin-labeled anti-mouse IgG1 and Qdot 605 streptavidin conjugate (G); biotin-labeled anti-mouse IgG2b and Qdot 605 streptavidin conjugate (H). (C) The area circled in yellow shows the T cell area. Original magnification, ×100.